Access
To read this story in full you will need to login or make a payment (see right).
Brief Communication
Nature Medicine 10, 1187 - 1189 (2004)
Published online: 24 October 2004 | doi:10.1038/nm1127
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells
Andrzej Ptasznik1,2, Yuji Nakata1,2, Anna Kalota1, Stephen G Emerson2 & Alan M. Gewirtz1
Abstract
We studied the effects of Lyn ablation on the survival of drug-resistant chronic myelogenous leukemia (CML) blast crisis cells using siRNA. Lyn siRNA reduced Lyn protein in both normal hematopoietic cells and BCR-ABL1-expressing (BCR-ABL1(+)) blasts by 80–95%. Within 48 h, siRNA-treated BCR-ABL1(+) blasts underwent apoptosis, whereas normal cells remained viable. This increased dependence on Lyn signaling for BCR-ABL1(+) blast survival provides the basis for rational treatment of drug-resistant CML blast crisis, particularly when lymphoid in nature.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Src kinases in Ph + lymphoblastic leukemiaNature Genetics News and Views (01 May 2004)
RESEARCH
SIGIRR, a negative regulator of Toll-like receptor?interleukin 1 receptor signalingNature Immunology Article (01 Sep 2003)
Dynamic programming of CD8 + T lymphocyte responsesNature Immunology Article (01 Apr 2003)
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phaseLeukemia Original Article
See all 44 matches for Research